Patent Application
20220088178
Incorporated by reference in its entirety herein is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: One 3,256 byte ASCII (text) file named “SeqList” created on Apr. 25, 2019.
The disclosure relates to vaccination strategies against human immunodeficiency virus (HIV), including methods of generating an immune response against HIV, vectors, compositions, and vaccination kits for use in the methods of generating an immune response against HIV.
Despite the success of antiretroviral treatment, human immunodeficiency virus (HIV) still causes millions of new infections every year, primarily in regions of the world with limited access to healthcare, making the need for a vaccine more apparent every year. To date, even the most successful HIV-1 vaccine clinical trial, the Phase III Thai Trial (also referenced herein as “RV144 Thai Trial” or “Thai Trial”) had only modest and short-lived efficacy (Rerks-Ngarm et al., 2009). The Thai Trial used a non-replicating canarypox viral vector (ALVAC) carrying recombinant genes for Gag, Pol and the surface subunit of the envelope (ENV) protein (gp120) followed by an AIDSVAX protein boost consisting of recombinant gp120 B/E produced in Chinese hamster ovary (CHO) cells. While ALVAC and AIDSVAX showed no protection when tested individually, their combination in RV144 has been shown to be modestly protective, providing valuable information on immune protection correlates. The most direct immune protection correlates pertain to antibody (Ab) responses against the V1-V2 loop of gp120. From these studies the importance of polyfunctional, non-neutralizing Abs (Haynes et al., 2012; Yates et al., 2014; Chung et al., 2014; Liao et al., 2013) has been shown. This short-lived humoral response faded over time and did not provide long-lasting protective advantage over the placebo arm (Yates et al., 2014). The results of the RV144 trial indicated the strength of a prime-boost approach integrating on a live vector with a subunit protein vaccine. The modest efficacy of the trial, however, also suggests that the particular combination of the specific antigens requires further study (Haynes et al., 2012; Yates et al., 2014; Corey et al., 2015; McMichael and Koff, 2014; Prentice et al., 2015). Accordingly, there is a significant need for new vaccination strategies against HIV.
The disclosure relates to the immunogenicity of virus-like particles (VLPs) produced by a replicating but highly attenuated vaccinia virus vector, a tobacco mosaic virus-based vector, a geminivirus-based vector, or combinations thereof. In certain embodiments, the disclosure is directed to composition comprising a vaccinia VLP and a plant-produced HIV VLP in sufficient amounts to generate an immune response in a mammalian subject against human immunodeficiency virus (HIV). The tobacco mosaic virus-based vector or the geminivirus-based vector expresses Gag, a fragment of gp41, or Gag and a fragment of gp41. In some aspects, geminivirus-based vector further comprises p19. The replicating but highly attenuated vaccinia virus vector expresses Gag, or a fragment of gp41 in certain embodiments, and may be based on NYVAC-KC. In some aspects, the fragment of gp41 is a membrane anchored truncated gp41 presenting the membrane proximal external region with its conserved broadly neutralizing epitopes in the perfusion conformation.
Exemplary embodiments also include a replicating but highly attenuated vaccinia virus vector expressing Gag or a fragment of gp41 and a tobacco mosaic virus-based vector or a geminivirus-based vector expressing Gag, a fragment of gp41, or Gag and a fragment of gp41 are disclosed along with VLPs produced from these vectors. The VLPs produced from the replicating but highly attenuated vaccinia virus vector are a vaccinia VLP presenting Gag, a fragment of gp41, or Gag and a fragment of gp41. The VLPs produced from the tobacco mosaic virus-based vector and the geminivirus-based vector may be plant-produced HIV VLPs presenting Gag and/or a fragment of gp41.
The disclosure is further related to methods of generating an immune response against HIV in a mammalian subject, wherein the subject is administered the vaccinia VLPs or the plant-produced HIV VLP. In some aspects, the methods relate to generating an HIV immune response in a mammalian subject. In some implementations, the mammalian subject is administered the vaccinia VLP and then the mammalian subject is administered the plant-produced HIV VLP at least 30 days later. In some aspects, the administration of the plant-produced HIV VLP is accompanied with administration of the vaccinia VLPs. In some implementations, the subject is administered a combination of the vaccinia VLPs and the plant-produced HIV VLP.
In certain embodiments, the method comprises administering a vaccinia VLP to the mammalian subject, wherein the vaccinia VLP presents HIV Gag and a fragment of gp41; and administering a plant-produced HIV VLP to the mammalian subject, wherein the plant-produced HIV VLP presents HIV Gag and a fragment of gp41 and is isolated from plant tissue transformed with a geminivirus-based plant expression vector. The vaccinia VLP is isolated from a mammalian cell transfected with at least one replicating but highly attenuated vaccinia virus vector and the mammalian subject is administered the vaccinia VLP and the plant-produced HIV VLP in an amount sufficient to generate an HIV immune response in the mammalian subject. In some aspects, the molar ratio of HIV Gag and the fragment of gp41 expressed by the plant produced HIV VLP is 1.7 to 11.8. In certain implementations, the mammalian subject is administered the vaccinia VLP at least 30 days prior to the administration of the plant-produced HIV VLP. In a particular implementation, the method further comprises administering to the mammalian subject a second dose of the plant-produced HIV VLP.
In some aspects, the geminivirus-based plant expression vector comprises a T-DNA region that comprises a first nucleic acid sequence encoding Gag and a first promoter region upstream of the first nucleic acid sequence encoding Gag; a second nucleic acid sequence encoding a fragment of gp41 and a second promoter upstream of the second nucleic acid sequence encoding a fragment of gp41. In certain embodiments, the T-DNA region of the geminivirus-based vector plant expression vector further comprises a nucleic acid sequence encoding at least one replication gene. In some aspects, the geminivirus-based vector is a bean yellow mosaic virus-based vector, the nucleic acid sequence encoding at least one replication gene that encodes Rep/RepA. The first promoter region and the second promoter region comprise a nucleic acid sequence encoding the cauliflower mosaic virus 35S promoter (P35). The first promoter region and the second promoter region further comprise two translation enhancer binding sites downstream of nucleic acid sequence encoding P35. In a particular implementation, the T-DNA region of the plant expression vector further comprises a pair of long intergenic regions, wherein the pair of long intergenic regions flank a portion of the T-DNA region that does not comprise the nucleic acid sequence encoding the silencing suppressor protein and does comprise the at least one replication gene, the first nucleic acid sequence encoding Gag and the first promoter region upstream of the first nucleic acid sequence encoding Gag; and/or the second nucleic acid sequence encoding a fragment of gp41 and a second promoter upstream of the second nucleic acid sequence encoding a fragment of gp41.
In some embodiments, the T-DNA region of the plant expression vector further comprises a nucleic acid sequence encoding a silencing suppressor protein, wherein the nucleic acid sequence encoding the silencing suppressor protein is upstream of the first nucleic acid sequence encoding Gag and the first promoter region upstream of the first nucleic acid sequence encoding Gag and upstream of the second nucleic acid sequence encoding a fragment of gp41 and a second promoter upstream of the second nucleic acid sequence encoding a fragment of gp41. In yet another embodiments, the T-DNA region of the plant expression vector further comprises a nucleic acid sequence encoding barley α-amylase signal peptide, wherein the nucleic acid sequence encoding barley α-amylase signal peptide is upstream of the second nucleic acid sequence encoding a fragment of gp41 and downstream of the second promoter region.
In some aspects, the at least one replicating but highly attenuated vaccinia virus vector is selected from the group consisting of: a first replicating but highly attenuated vaccinia virus vector comprising a third nucleic acid sequence encoding Gag, a second replicating but highly attenuated vaccinia virus vector comprising a fourth nucleic acid sequence encoding a fragment of gp41, and a third replicating but highly attenuated vaccinia virus vector comprising the third nucleic acid sequence encoding Gag and the fourth nucleic acid sequence encoding fragment of gp41. In some aspects, the replicating but highly attenuated vaccinia virus vector is NYVAC. In certain implementations, the vaccinia VLP administered presents both Gap and dgp41. Thus, the at least one replicating but highly attenuated vaccinia virus vector is a replicating but highly attenuated vaccinia virus vector comprising the third nucleic acid sequence encoding Gag and the fourth nucleic acid sequence encoding fragment of gp41.
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
Detailed aspects and applications of the disclosure are described below in the following drawings and detailed description of the technology. Unless specifically noted, it is intended that the words and phrases in the specification and the claims be given their plain, ordinary, and accustomed meaning to those of ordinary skill in the applicable arts.
In the following description, and for the purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of the various aspects of the disclosure. It will be understood, however, by those skilled in the relevant arts, that embodiments of the technology disclosed herein may be practiced without these specific details. It should be noted that there are many different and alternative configurations, devices and technologies to which the disclosed technologies may be applied. The full scope of the technology disclosed herein is not limited to the examples that are described below.
The singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a step” includes reference to one or more of such steps.
As used herein, the term “virus-like particle” or “VLP” refers to multiple protein structure that mimic the organization and conformation of authentic native viruses but lack the viral genome. In some embodiments, expression of viral structural proteins, for example capsid or envelope proteins, result in the self-assembly of VLPs. In other embodiments, a viral core is required to facilitate the assembly of the VLP when fragments of a protein are the desired presentation targets at the surface of the VLP. Viral cores used in the design of VLPs include bacteriophage MS2, adeno-associated virus, adenovirus, and tobacco mosaic virus.
As referenced herein, the nucleic acid sequence of Gag has at least 95% identity with the nucleic acid sequence of Accession No. AY805330 or Accession No. JX534517.
As used herein, the term “dgp41” refers to a membrane anchored truncated gp41 presenting the membrane proximal external region with its conserved broadly neutralizing epitopes in the prefusion conformation. As referenced herein, the nucleic acid sequence of dgp41 has at least 95% identity with the nucleic acid sequence of Accession No. AF075722, Accession No. AY805330, or Accession No. JX534518.
The disclosure relates to a vaccination strategy against human immunodeficiency virus (HIV) using VLPs presenting Gag and/or dgp41. VLPs are safe, yet immunogenic, components of several vaccines and candidate vaccines for multiple infectious diseases (for a review see Kushnir et al., 2012). The potential for success of VLP-based vaccines is indicated by the widespread use of the human papillomavirus (HPV) vaccines Gardasil® (Merck and Co, 2006) and Cervarix® (GlaxoSmithKline, 2014). To date, many plant-produced vaccines have been tested in animal studies for immunogenicity for both human and veterinary diseases (Rybicki, 2010; Scotti and Rybicki, 2013). Additionally, VLPs, but not soluble subunit vaccines, are more likely to properly induce innate and low affinity B cells to transport and display antigen to induce Ab responses (Bessa et al., 2012; Link et al., 2012).
In some aspects, the disclosure is directed to a replicating but highly attenuated vaccinia virus for expressing Gag and/or dgp41. Upon infection of mammalian cells with the vaccinia virus, VLPs presenting Gag and/or dgp41 are produced. In other aspects, the disclosure is directed to a HIV VLP produced from a tobacco mosaic virus-based vector (magnICON) or a geminivirus-based vector. The tobacco mosaic virus-based vector and geminivirus-based vector are designed for expression of the HIV VLP in plants. Accordingly, the disclosure also relates to optimized methods of purifying the HIV VLP from plants to reduce the amount of protein contaminants, for example rubisco (Ribulose-1,5-bisphosphate carboxylase/oxygenase). The disclosure is also encompasses vector compositions for producing vaccinia VLPs and plant-produced HIV VLPs that generate an immune response against HIV in a mammalian subject, particularly HIV-1.
In other aspects, the disclosure is directed to methods of generating an immune response against HIV, particularly HIV-1, in a mammalian subject using the VLPs described herein.
In some implementations, the methods of generating an immune response against HIV in a mammalian subject comprises administering the VLP described herein to the mammalian subject on two separate occasions, for example, at least 30 days apart. In certain implementations, the two administrations of the VLP are 45 days apart. In one implementation, the VLP administered in both instances are plant-produced HIV VLPs. Plant-produced HIV VLPs are immunogenic in mice and can elicit antibodies specific to the MPER broadly neutralizing antibody (bnAb) target in the dgp41 protein (
In a particular embodiment, the method of generating an immune response against HIV in a mammalian subject comprising exposing the mammalian subject to a VLP presenting Gag and/or a fragment of gp41 (for example, dgp41) on three separate occasions, wherein each exposure is at least 30 days apart, for example 45 days apart. In some aspects, the first exposure comprises administration of attenuated vaccinia virus expressing Gag and/or dgp41 to the mammalian subject, which results in exposure to vaccinia VLPs presenting Gag and/or dgp41, while the second exposure and third exposure comprise administration of a plant-produced HIV VLP to the mammalian subject. In some implementations, an adjuvant is administered with the plant-produced HIV VLP. In certain embodiments, the HIV VLPs administered in the second and third exposure are produced from a plant transformed with a tobacco mosaic virus-based vector (magnICON) or a geminivirus-based vector expressing Gag and/or dgp41. In particular implementations, the second exposure and third exposure further comprise administration of attenuated vaccinia virus expressing Gag and/or dgp41. In certain implementations, the amount of plant-produced HIV VLP administered to a mammalian subject per exposure that sufficient to ultimately generate an HIV immune response in the mammalian subject is between 1.5 and 3 μg Gag (p24) and between 0.75 and 2.5 μg dpg41 (MPER), between 1.75 and 2.25 μg Gag and between 0.95 and 1.45 μg dpg41, or preferably about 2 μg Gag and about 1.2 μg dpg41. In some aspects, the molar ratio of dpg41 to Gag is at least 1.7 or between 1.7-11.8. In some aspects, the total amount of Gag and dpg41 administered per exposure is between 60 and 400 μg for each antigen, between 100 and 350 μg for each antigen, between 150 and 300 μg for each antigen, between 250 and 250 μg for each antigen, or preferably 300 μg for each antigen. Thus, in some aspects, the disclosure relates to a composition comprising a plant-produced HIV VLPs and vaccinia VLP.
This vaccine strategy is based on two discoveries. The first is that replicating vectors, in addition to their excellent facility in eliciting T cell responses, are expected to increase antigen load, resulting in improved immunogenicity. The second is that VLPs improve presentation of relevant neutralizing determinants to the immune system. In particular, the inventors developed replicating vaccinia virus vectors based on NYVAC-KC that express Gag and dgp41 of HIV-1 as matching antigens to the plant-produced VLPs for prime/boosting purposes. The HIV membrane protein gp41 contains the bnAb target known as the MPER. This region requires the context of a membrane in order to elicit the partially auto-reactive bnAbs found in HIV-infected patients (Verkoczy et al., 2010, 2013; Haynes et al., 2005; Zhang et al., 2016). In some implementations, the method further comprises administering to the subject a plant-produced HIV VLP. Accordingly, in some embodiments, the methods comprise administering together the combination of NYVAC-KC-Gag/dgp41 replicating vaccinia virus vectors in a regimen closely mimicking the RV144 clinical trial.
Despite the poor priming capacity of the vaccinia VLP (VV) in terms of eliciting antibody responses against Gag and gp41, upon boosting with plant-derived HIV VLPs at Day 45, antibody (Ab) production spiked with another increase after the final immunization at Day 97 (
In some aspects, the method induces systemic and mucosal antibody responses to Gag and dgp41 with a bias towards IgG1. For example, the methods of generating an immune response against HIV in a mammalian subject produce robust Gag-specific CD8 T cell responses. Gag-specific CD8 T cell responses were highest in the group boosted with VV+VLPs (Group 3), reaching 12.7% of CD8 T cells expressing IFN-γ in response to the five Gag peptides (
As shown in the animal study of Example 1, the described VLPs produced from the vaccinia virus vector and the plant-produced HIV VLPs work in concert to elicit Gag-specific CD8 T cell responses and both systemic and mucosal antibodies to Gag and dgp41 peptides in the immunization group which most closely mimics the Thai Trial. The vaccina virus vector is developed from the NYVAC strain previously rendered replication incompetent in human cells by deletion of 18 open reading frames from the genome of Copenhagen (Cop), its parental strain (Tartaglia et al., 1992a). NYVAC-KC contains a reinsertion of two host-range genes, K1L and C7L, which allows the virus to replicate in human tissue, thus improving immunogenicity while remaining highly attenuated (Kibler et al., 2011; Quakkelaar et al., 2011).
Because of the surface exposure, immunogenicity, and the critical roles during target-cell infection of HIV envelope protein (Env/gp120), this protein has been a natural target for vaccine development since the early days of HIV-1 research (Burton and Mascola, 2015; Mascola and Haynes, 2013). However, targeting gp120 in the development of an HIV vaccine has proven to be far from straightforward. gp120 is not highly conserved, and many critical neutralization targets are hidden or are only exposed upon conformational change during viral entry, thus limiting the effectiveness of any NAb response to this antigen (Pancera et al., 2014; Decker et al., 2005; Labrijn et al., 2003). Thus, gp120 functions as a highly mutable decoy with most of its functionally important immunogenic sites conformationally occluded or shielded by glycans. In fact, monomeric preparations of gp120, as well as various preparations aimed at presentation of gp120 trimers, have repeatedly failed to induce protective immune responses in animal models or humans, with the sole and modest exception of the RV144 Thai Trial (also referenced herein as “Thai Trial”) (McGuire et al., 2014; Jacob et al., 2015; Moore et al., 2015; Haynes et al., 2016).
The Thai Trial demonstrated the strength of prime/boost vaccination approach by effectively combining two components that were previously shown to be ineffective on their own: a live (albeit non-replicating) canarypox viral vector (ALVAC) and a soluble protein boost (AIDSVAX). The low efficacy of the trial left much to be desired for widespread use as a vaccine while providing the conceptual basis for further improvement (Rerks-Ngarm et al., 2009). Protein engineering has attempted to resolve many of the issues of targeting gp120, including the design of SOSIP trimeric gp140 variants of Env to make a more structurally accurate target necessary for eliciting specific types of NAbs, including a design to specifically target nAb germline B cells (Jardine et al., 2013; Billington et al., 2007; Du et al., 2009; Sellhorn et al., 2012; Wan et al., 2009). To date, no successful clinical trials incorporating an engineered gp140 antigen have been conducted.
An optimized nucleic acid sequence encoding Gag for VLP formation was previously described (Kessans et al., 2013). As described herein, the optimized Gag sequence is suitable for VLP formation using a vaccinia virus vector, tobacco mosaic virus-based vector, and geminivirus-based vector. In some aspects, the nucleic acid sequence of the optimized Gag comprises the nucleic acid sequence of Accession No. JX534517. In other aspects, the nucleic acid sequence of the optimized Gag has at least 95% identity with the nucleic acid sequence of Accession No. JX534517. In some embodiments, the
2. gp41
Whereas many studies have examined the immunogenicity of Gag, far fewer studies have examined gp41. The gp41 protein of HIV is the transmembrane portion of the HIV surface spike and contains the highly immunogenic membrane proximal external region (MPER), a target of many broadly neutralizing antibodies (bnAbs) (Purtscher et al., 1994; Zwick et al., 2001; Huang et al., 2012). gp41 contains highly immunogenic determinants that induce production of Abs that are among the first to arise during acute HIV-1 infection but are of very limited protective value, showing little or no antiviral activities (Burton and Mascola, 2015; Liao et al., 2011; Bonsignori et al., 2012). These immunodominant epitopes are located in a region of the protein spanning the two heptad repeat domains and in particular within the loop that connects them (Zolla-Pazner, 2004) and are exposed on the gp41 “stump” in its six-helical bundle conformation upon removal of the gp120 subunit (Burton and Mascola, 2015). Still, gp41 was found to be the target of a number of broadly neutralizing Abs (bnAbs) directed against conformational (35O22 binding at the gp41-gp120 interface) (Huang et al., 2014) and linear epitopes (2F5, 4E10, Z13 and 10E8 that recognize closely situated sites within the membrane proximal external region, MPER) (Parker et al., 2001; Cardoso et al., 2005; Nelson et al., 2007; Huang et al., 2012).
Beyond neutralization, anti-MPER Abs, including the above-mentioned bnAbs, were found to exhibit other potent anti-HIV-1 activities including transcytosis blockade (Tudor et al., 2012; Shen et al., 2010; Matoba et al., 2004, 2008, 2009), Ab-dependent cell-mediated cytotoxicity (ADCC) (Tudor and Bomsel, 2011; Hessell et al., 2007) and curbing of dendritic cell-mediated trans-infection (Tudor et al., 2012; Sagar et al., 2012; Magerus-Chatinet et al., 2007). Moreover, passive immunization with these bnAbs provided impressive protection against mucosal transmission of a simian-HIV hybrid (SHIV) in the macaque model (Baba et al., 2000; Hessell et al., 2010; Klein et al., 2013a). Anti-MPER Abs with anti-viral activities were also described in mucosal secretions of highly-exposed but seronegative individuals (Kaul et al., 1999, 2001; Pastori et al., 2000; Devito et al., 2000a, 2000b; Tudor et al., 2009). Lastly, anti-MPER Abs that were passively passed through breast milk from infected mothers to their uninfected babies were correlated with protection (Diomede et al., 2012; Pollara et al., 2015).
Despite their long-standing promise, anti-MPER bnAbs are naturally rare and are notoriously difficult to elicit. For example, less than 25% of HIV-1-infected patients develop broad and potent nAbs, which even if present require ˜2-4 years to produce (Burton and Mascola, 2015; Mascola and Haynes, 2013; Haynes et al., 2016; Mascola and Montefiori, 2010). Several explanations have been suggested, including a lengthy maturation process involving many somatic mutations and extensive affinity maturation (Klein et al., 2013b; Kepler et al., 2014), and clonal deletion of the B-cell lines secreting such bnAbs that were shown to be partially autoreactive (Verkoczy et al., 2010, 2011, 2013). Interestingly, many of the autoreactivity targets are lipids that can be found in both the plasma membrane of the host cell and in the viral envelope (Haynes et al., 2005; Alam et al., 2007, 2009; Irimia et al., 2016).
It is widely accepted that the membrane milieu of the MPER region plays a major role in the functional immunogenicity of gp41 (Alam et al., 2009; Chen et al., 2014). Both the metastable native conformation of the gp120-gp41 trimer and the highly stable post-fusion conformations do not expose the neutralizing epitopes (Frey et al., 2008, 2010; Buzon et al., 2010; Pancera et al., 2014), and fail to efficiently elicit bnAbs (Williams et al., 2015; Sanders et al., 2015; Crooks et al., 2015; Davis et al., 2009; Decker et al., 2005; Labrijn et al., 2003) or engage the germline B cell precursors for specific bnAbs (McGuire et al., 2014; Hoot et al., 2013; Jardine et al., 2013).
An effective MPER-based antigen therefore requires presentation of the MPER within a context of a membrane and exposure of the region in a conformation mimicking the putative prefusion intermediate. In part, this is because many of the apparent interactions between the amphipathic peptide and the membrane affect the ability of the region to interact with bnAbs (Haynes et al., 2005; Verkoczy et al., 2010; Williams et al., 2015; Haynes et al., 2016; Zhang et al., 2016). This antigenic region when presented correctly on a membrane has strong potential as a vaccine component. Displaying the MPER in a virosome successfully elicited mucosal and systemic Abs with transcytosis-blocking activity in a Phase I clinical trial (Leroux-Roels et al., 2013). Bomsel and co-workers used a gp41 peptide (residues 649-684) spanning the MPER and part of the C-terminal heptad repeat to decorate liposomes (“virosome”), and the virosome elicited protective responses against SHIV infection in the macaque model (Bomsel et al., 2011). VLPs displaying gp41 can elicit both systemic and mucosal Abs to this region (Kessans et al., 2016) and transcytosis blocking Abs to this region are achievable (Matoba et al., 2008).
As described herein, a fragment of gp41 that comprises a membrane anchored truncated gp41 presenting the membrane proximal external region with its conserved broadly neutralizing epitopes in the prefusion conformation is suitable for triggering an immune response against HIV. In some aspects, the fragment of gp41 is dgp41. In certain embodiments, the nucleic acid sequence of dgp41 comprises the nucleic acid sequence of Accession No. JX534518. In other embodiments, the nucleic acid sequence of dgp41 has at least 95% identity with the nucleic acid sequence of Accession No. JX534518. In some aspects, the nucleic acid sequence of dgp41 is the nucleic sequence of the digestion fragment pTM 602 using the restriction enzymes NcoI and SacI.
Live recombinant vectors based on viruses belonging to a wide range of families such as adenoviridae, poxviridae, and herpesviridae have been previously tested for their immunogenicity (Rerks-Ngarm et al., 2009; Hansen et al., 2013a; Huang et al., 2015; Buchbinder et al., 2008; Tartaglia et al., 1992b). The relative success of ALVAC within the context of RV144 increased the focus on poxviruses (see Gomez et al., 2012a; Pantaleo et al., 2010; Jacobs et al., 2009). ALVAC is based on canarypox, which like other avipoxviruses is naturally attenuated in humans due to its restricted replication in non-avian cells (Taylor and Paoletti, 1988; Taylor et al., 1988) accounting for ALVAC's high safety profile (Team AVEGP, 2001; Nitayaphan et al., 2004). Similarly, when developing vaccinia-based vaccine vectors, efforts were initially focused on strains that are non-replicating in human cells (e.g. MVA and NYVAC), due to safety concerns over potential complications with VACV infection in immune-compromised individuals.
Live viral vectors are appealing as vaccine vehicles for the expression of HIV-1 antigens due to their proficiency for eliciting T cell responses. For example, a cytomegalovirus (CMV) vector was recently shown in nonhuman primates to clear an established SIV infection with dependency on CD8 T cells recognizing non-canonical epitopes on major histocompatibility complex (MHC) II instead of WIC I (Hansen et al., 2013a, 2013b). Poxviruses also stand out amongst other viral vectors [see reviews (Gomez et al., 2012a; Pantaleo et al., 2010; Jacobs et al., 2009)] as attested by the Thai Trial that employed a canarypox-based vector and was the first and only HIV-1 vaccine clinical trial to show efficacy (Rerks-Ngarm et al., 2009; Haynes et al., 2012). The canarypox-based viral vector used in the trial, ALVAC, is not capable of replication in mammalian cells (Taylor and Paoletti, 1988; Taylor et al., 1988). Inability to replicate in vivo in humans makes the virus safer to use as a vaccine or a vaccine vector. However, as described herein, replication could enhance immunogenicity by increasing antigen load as the virus replicates in vivo.
Intensive research led to partial uncoupling of attenuation and replication in NYVAC-based vectors showing enhanced immunogenicity without compromising their safety. Specifically, reinsertion of two host-range genes yielded NYVAC-KC. This strain is capable of replicating in human cells and displays enhanced immune activation, yet it remains highly attenuated in a mouse model of pathogenesis (Kibler et al., 2011; Quakkelaar et al., 2011), thus giving this particular vector many desirable traits of a vaccine vector and was chosen for use in the work presented here. NYVAC was originally designed as a highly attenuated vaccine vector by specifically deleting 18 open reading frames from its parental strain (Cop), thus preventing its replication in humans (Tartaglia et al., 1992b). NYVAC has been tested as an HIV vaccine vector and was shown to induce robust, polyfunctional CD4 and CD8 T cell responses to Env and Gag-Pol-Nef (GPN) antigens in vaccinated individuals (Harari et al., 2008, 2012). Because mucosal immune responses are thought to be particularly important in protection against HIV-1, it was significant to note that such responses could be detected in the gut of NYVAC-immunized patients (Perreau et al., 2011). More recently, intensive research led to partial uncoupling of attenuation and replication in NYVAC-based vectors showing enhanced immunogenicity without compromising their safety. Specifically, reinsertion of two host-range genes yielded NYVAC-KC. The NYVAC-KC vector is a replicating, but safe, live viral vector with which induces higher Gag-specific CD8 T cell responses than with non-replicating poxviral vaccine vectors, although a direct comparison has yet to be performed. NYVAC-KC is capable of replicating in human cells and displays enhanced immune activation, yet it remains highly attenuated in a mouse model of pathogenesis (Kibler et al., 2011; Quakkelaar et al., 2011), thus giving this particular vector many desirable traits of a vaccine vector and was chosen for use in the vaccine strategy described herein.
In some embodiments, the vaccine design strategy disclosed herein utilized the replicating vaccinia strain NYVAC-KC to express the full-length Gag or a fragment gp41 of HIV, for example a membrane anchored truncated gp41 presenting the membrane proximal external region with its conserved broadly neutralizing epitopes in the prefusion conformation (dgp41). As is well understood in the art, recombinant vaccinia virus is produced by inserting foreign genes into the thymidine kinase (TK) gene using homologous recombination. This is achieved by a recombination plasmid containing the TK locus with the foreign gene inserted between the homologous recombination arms. Accordingly, the vaccinia vector described herein comprises a nucleic acid encoding Gag or a fragment of gp41 (for example, dgp41) in the TK locus between the homologous recombination arms.
Vaccinia VLPs presenting Gag, a fragment of gp41 (for example, dgp41), or both can be produced from the described vaccinia vector by transfecting mammalian cells with these vectors and infecting the transformed mammalian cells with a replicating but highly attenuated vaccinia virus (for example NYVAC). Transfecting the mammalian cells with a vaccinia vector expressing Gag produces VLPs presenting Gag upon viral infection, while transfecting the mammalian cells with vaccinia vector expressing dgp41 produces VLPs presenting dgp41 upon viral infection. If the mammalian cells are transfected with both a vaccinia vector comprising Gag and a vaccinia vector comprising dgp41, however, then VLPs presenting Gag and dgp41 are produced. These VLPs can be administered to a mammalian subject to prime an immune response against HIV, for example, when used in combination with the HIV VLPs described herein. In some implementations, NYVAC-KC for expression of Gag and NYVAC-KC for expression of dgp41 of HIV-1 are used as matching antigens to the plant-produced VLPs for prime/boosting purposes. Accordingly, the disclosure relates to compositions comprising a replicating and highly-attenuated vaccinia virus vector expressing Gag and/or replicating and highly-attenuated vaccinia virus expressing a fragment of gp41 of HIV along with a construct for the expression of HIV VLP in plants. The vaccine strategy targets gp41 of HIV.
Infecting susceptible cells with NYVAC-KC-Gag with or without NYVAC-KC-dgp41 releases, respectively, ˜100 nm Gag or Gag/dgp41 VLPs into the extracellular medium (
Accordingly, in another embodiment, the vaccinia virus vector co-expresses Gag and dgp41 from the same locus to ensure in vivo Gag/dgp41 VLP formation. As such, in some aspects, the vaccinia virus vector comprises a nucleic acid encoding Gag and a fragment of gp41 (for example, dgp41) in the TK locus between the homologous recombination arms. VLPs produced from infecting mammalian cells with this vaccinia virus vector, which would express Gag and dgp41, are also suitable for priming an immune response against HIV, for example, when used in combination with the HIV VLPs described herein.
Another explanation for the limited functionality of the dual vectors is the poor replication and/or spread in mice. In some aspects, poor replication and/or spread of the vectors is due to the cytotoxicity represented by protein precipitates in the cytoplasm and nuclear condensation in NYVAC-KC-Gag-, dgp41- or co-infected cells (
Plant production of recombinant proteins and pharmaceuticals offers multiple advantages, including lack of contamination by mammalian pathogens, less expensive scale-up, speed of expression, and platform flexibility (Horn et al., 2003; Ma et al., 2005; Daniell et al., 2009; Rybicki, 2009, 2010; Egelkrout et al., 2012). Many different types of VLPs have been produced in plants, for review see (Chen and Lai, 2013; Scotti and Rybicki, 2013). Several plant-made products have been tested in human clinical trials (Ma et al., 2005; Yusibov et al., 2014) and one product has been approved by the FDA for treatment of Gaucher disease (Zimran et al., 2011). Economic viability of plant production relies heavily on oftentimes poor yields, and downstream processing costs to remove host proteins accounts for ˜80% of production expenditures (Egelkrout et al., 2012; Wilken and Nikolov, 2012).
Several transient deconstructed viral-based vectors for rapid, high level protein expression in plants are currently available. The tobacco mosaic virus (TMV)-based magnICON system has been extensively used to express recombinant proteins in plants since its invention and was the first to provide gram-levels of antigen (Marillonnet et al., 2004; Gleba et al., 2005; Marillonnet et al., 2005). However, other expression systems based on other plant viruses such as geminiviruses (Gemini) (Mor et al., 2003; Huang et al., 2009) and Cowpea mosaic virus (CPMV)-based pEAQ vectors (Sainsbury et al., 2009; Peyret and Lomonossoff, 2013) are less well characterized. The TMV system requires simultaneous delivery of three plasmids by Agrobacterium tumefaciens infiltration (agroinfiltration) to recombine in planta within the nucleus and the TMV movement protein transfers amplified mRNA to surrounding cells (Marillonnet et al., 2004). However, Gemini vectors are single plasmid delivery yet lack a movement protein and are known to induce gene silencing (Seemanpillai et al., 2003; Rodriguez-Negrete et al., 2009; Aregger et al., 2012) but this can be suppressed using the Tomato bushy stunt virus p19 protein (Silhavy et al., 2002; Voinnet et al., 2003; Garabagi et al., 2012). Furthermore, multiple proteins can be delivered on the same plasmid and expressed in separate replicons established by short and long intergenic regions (SIR/LIR) (Huang et al., 2009). After transfer to the nucleus, Gemini DNA is amplified via rolling-circle mechanism by the C1/C2 (Rep/RepA) proteins (Gutierrez, 1999; Mor et al., 2003).
HIV VLPs have been produced in plants with low yield, particularly of full-length Gag, being a common theme (Meyers et al., 2008; Kessans et al., 2013). Yield can be increased by expressing Gag in transgenic chloroplasts (Scotti et al., 2009). An efficient production method for enveloped VLPs in the tobacco-relative Nicotiana benthamiana, consisting of Gag and deconstructed-gp41 (dgp41:MPER, transmembrane domain, and full-length cytoplasmic tail) was developed (Kessans et al., 2013). Such VLPs display the MPER of gp41 without steric hindrance from gp120, without the immunodominant epitopes on both Env subunits, and with a higher antigen load per VLP than what exists in an HIV virion (Kessans et al., 2016). A similar construct has been shown by us to be a likely trimer with its bnAb epitopes exposed (Gong et al., 2015). When administered to mice, these VLPs elicit both serum IgG and mucosal IgA to Gag and dgp41 antigens (Kessans et al., 2016).
The described plant-produced HIV VLPs comprising full length Gag and a fragment of gp41 have the advantage of displaying the MPER of gp41 in the native context of a Gag matrix, providing an immunogenic platform for humoral responses to both antigens (Kessans et al., 2013, 2016). Additionally, HIV VLPs have been shown to boost T cell responses following a heterologous prime (Chapman et al., 2013; Chege et al., 2008; Pillay et al., 2010). CD8 T cell responses, often targeting the Gag protein, are known to be associated with reduced viral load, making this a key target for protective T cell immunity (Kiepiela et al., 2007; Koup et al., 1994; Mudd et al., 2012; Stephenson et al., 2012; Jiao et al., 2006). Plant-produced VLPs show proficiency for eliciting high Ab titers and may boost T cell responses primed by the NYVAC-KC vectors.
The primary roadblocks to plant-produced pharmaceuticals revolve around both purification and low yield/expression levels (Wilken and Nikolov, 2012). Recombinant protein often accounts for only 0.7-7% of total soluble protein (TSP) (Egelkrout et al., 2012) whereas rubisco is the most prominent soluble protein, and the most abundant protein in the world, at 30-50% of the plant TSP (Spreitzer and Salvucci, 2002; Feller et al., 2008). Removal of rubisco has plagued the plant-produced pharmaceutical field; however, recent developments show great promise at removing rubisco with simple chromatography and precipitation methods (Buyel et al., 2013; Buyel and Fischer, 2014; Arfi et al., 2016). One such study reports the ability to remove up to 92% of rubisco from plant extractions using polyethylene glycol (PEG) precipitation (Arfi et al., 2016). Described herein is a method for removing the primary large and small subunit bands of rubisco from our VLP preparations by simple ammonium sulfate precipitation (
a. Tobacco Mosaic Virus-Based Vector
The tobacco mosaic virus (TMV)-based magnICON system has been extensively used to express recombinant proteins in plants since its invention and was the first to provide gram-levels of antigen (Marillonnet et al., 2004; Gleba et al., 2005; Marillonnet et al., 2005). In some aspects, a tobacco mosaic virus-based vector encoding Gag and/or dgp41 is used to produce the HIV VLP. Accordingly, the tobacco mosaic virus-based vector comprises a T-DNA region comprising a nucleic acid sequence encoding Gag, dgp41, or both Gag and dgp41. In some embodiments, expression of Gag, dgp41, or a nucleic acid sequence encoding both Gag and dpf41 is driven by the nopaline synthase (NOS) promoter. In some embodiments, expression of Gag, dgp41, or a nucleic acid sequence encoding both Gag and dpf41 is driven by the cauliflower mosaic virus 35S promoter (P35). In some aspects, a nucleic acid sequence encoding an attB site is upstream of the nucleic acid sequence encoding Gag, dgp41, or both Gag and dgp41 and is downstream of the promoter.
The TMV system requires simultaneous delivery of three plasmids by Agrobacterium tumefaciens infiltration (agroinfiltration) to recombine in planta within the nucleus and the TMV movement protein transfers amplified mRNA to surrounding cells (Marillonnet et al., 2004).
b. Geminivirus-Based Vector
In other aspects, a geminivirus-based vector encoding Gag and/or dgp41 is used to produce the HIV VLP. Geminivirus-based vectors are single plasmid delivery that lack a movement protein and are known to induce gene silencing (Seemanpillai et al., 2003; Rodriguez-Negrete et al., 2009; Aregger et al., 2012) but this can be suppressed using the Tomato bushy stunt virus p19 protein (Silhavy et al., 2002; Voinnet et al., 2003; Garabagi et al., 2012). Furthermore, multiple proteins can be delivered on the same geminivirus-based plasmid and expressed in separate replicons established by short and long intergenic regions (SIR/LIR) (Huang et al., 2009). After transfer to the nucleus, Gemini DNA is amplified via rolling-circle mechanism by the C1/C2 (Rep/RepA) proteins (Gutierrez, 1999; Mor et al., 2003).
In some aspects, the geminivirus-based vector is a vector based on bean yellow dwarf virus (BYDV). Accordingly, the geminivirus-based vector comprises a T-DNA region comprising at least one replicon gene and a nucleic acid sequence encoding Gag and/or a nucleic acid encoding dgp41, wherein the at least one replicon gene is downstream of the nucleic acid sequence encoding Gag and the nucleic acid encoding dgp41. Where the T-DNA region of the geminivirus-based vector comprises a nucleic acid sequence encoding Gag and a nucleic acid encoding dgp41, in some embodiments, the nucleic acid sequence encoding dgp41 is upstream of the nucleic acid sequence encoding Gag. In some embodiments, the T-DNA region comprises a nucleic acid encoding Rep/RepA. In certain embodiments, the BYDV short intergenic region is upstream of Rep/RepA.
In some embodiments of the geminivirus-based vector, Gag and dgp41 expression is under the control of P35. Thus, in certain embodiments of the geminivirus-based vector, the T-DNA region further comprises a promoter upstream of the nucleic acid sequence encoding Gag and the nucleic acid encoding dgp41, where the promoter region comprises a nucleic acid sequence encoding P35. In some aspects, the promoter region further comprises two translation enhancer binding sites (2e), which are downstream of the nucleic acid sequence encoding P35. In certain embodiments, the geminivirus-based vector further comprises a barley α-amylase signal peptide upstream of the nucleic acid encoding dgp41 but downstream of the promoter region.
In some aspects, the T-DNA region of the geminivirus-based vector also comprises two BYDV long intergenic regions. One long intergenic region is upstream of the promoter region, and one long intergenic region is downstream of the at least one replicon gene. Where the T-DNA region of the geminivirus-based vector comprises a nucleic acid sequence encoding Gag controlled by one promoter region and a nucleic acid encoding dgp41 controlled by another promoter region, the long intergenic regions flank the portion of the T-DNA region containing the nucleic acid sequence encoding Gag, the nucleic acid encoding dgp41, and the at least one replication gene.
In particular embodiments, the T-DNA region of the geminivirus-based vector further comprises a nucleic acid sequence encoding a silencing suppressor protein. In some aspects, the silencing suppressor protein is p19, for example, tomato bushy stunt virus p19. The expression of the silencing suppressor protein by the geminivirus-based vector delays the onset of plant cell necrosis when compared with plant cells transformed with geminivirus-based vectors lacking a nucleic acid sequence encoding the silencing suppressor protein. The nucleic acid sequence encoding the silencing suppressor protein is upstream of the nucleic acid sequence encoding Gag and the nucleic acid encoding dgp41 and is upstream of the region flanked by the long intergenic regions. In some aspects, expression is silencing suppressor protein is controlled by a promoter downstream of the nucleic acid sequence encoding the silencing suppressor protein. In certain embodiments, the promoter is NOS.
The disclosure is further illustrated by the following examples that should not be construed as limiting. The contents of all references, patents, and published patent applications cited throughout this application, as well as the figures, are incorporated herein by reference in their entirety for all purposes.
a. Materials and Methods
i. Cloning pGNR Plasmids for Virus Recombination
Construction of synthetic genes encoding Gag (from subtype C R5 HIV-1 isolate 1084i, GenBank #AY805330; synthetic construct GenBank #JX534517) and dgp41 (MPER derived from the B-clade MN isolate, GenBank #AF075722, transmembrane and C-terminal domains from the 1084i isolate #AY805330; synthetic construct #JX534518) was previously described (Kessans et al., 2013). The genes were cloned into the pGNR plasmid, which harbors a neoGFP selection cassette (neomycin resistance gene fused to GFP, known as pGNR) between homologous recombination arms for the vaccinia TK locus. Gag and dgp41 genes were amplified from pTM 488 (Gag) and pTM 602 (dgp41) [described in (Kessans et al., 2013)] into TOPO pCR-2.1 vectors (Invitrogen). Cloning was achieved using AccuStart Taq DNA polymerase HiFi PCR kit (Quanta Biosciences) with primers oTM 664 (SEQ ID NO. 1: 5′-ACTAGTATGGGAGCTAGAGCCTCT-3′) and 665 1 (SEQ ID NO. 2: 5′-CCCGGGTTATTGAGAGGAAG-3′) for Gag and oTM 666 (SEQ ID NO. 3: 5′-ACTAGTATGGGATCTCAAACTCAACAA-3′) and 1667 (SEQ ID NO. 4: 5′-CCCGGGTTATTGCAAAGCAG-3′) for dgp41 for the addition of 5′ flanking SpeI and 3′ flanking XmaI sites, denoted in italics. Ligation reactions were electroporated into DH5 α Escherichia coli and plated onto LB +ampicillin plates. Gene insertion was confirmed by colony PCR using GoTaq Green Master Mix (Promega). Plasmids were extracted using the E.Z.N.A. mini-prep kit (Omega) and sequences verified using backbone-specific primers M13-forward and M13-reverse. The TOPO plasmids were designated pTM 813 (Gag) and pTM 814 (dgp41). Both pTM 813, 814, and pGNR were digested with SpeI and XmaI (NEB) and fragments separated via gel electrophoresis and extracted using QIAquick Gel Extraction Kit (Qiagen), then ligated into the pGNR backbone using T4 DNA ligase (Promega). Ampicillin resistant DH5a E. coli colonies were screened by colony PCR and plasmids extracted as above. Sequences were confirmed with pGNR backbone-specific primers oTM 686 (SEQ ID NO. 5: 5′-CCCACCCGCTTTTTATAGTAA-3′) and 687 (SEQ ID NO. 6: 5′-CGGTTTATCTAACGACACAACA-3′). Sequence-verified pGNR plasmids were named pTM 815 (Gag) and pTM 816 (dgp41).
ii. Cell Lines and Viruses
Monkey kidney BSC-40 cells were grown in DMEM (Corning Cellgro) with 5% FBS plus gentamycin and 2 mM L-glutamine. Baby hamster kidney BHK cells were grown in MEM (Corning Cellgro) with 5% FBS plus gentamycin. Generation of the parental vaccinia virus (VACV) strain NYVAC-KC was described previously (Kibler et al., 2011).
iii. In Vivo Recombination (IVR)
Simultaneous transfection/infection [in vivo recombination, IVR (Kibler et al., 1997; Brandt and Jacobs, 2001)] was performed with pTM 815 (Gag) and pTM 816 (dgp41) and NYVAC-KC to insert Gag and dgp41 into the vaccinia virus TK locus. 500 ng of plasmid DNA was transfected using Lipofectamine and Plus™ Reagent (Invitrogen) per manufacturer's protocol. This was immediately followed by infection with NYVAC-KC at an MOI=0.01 in 35 mm2 dishes of BSC-40 cells. Recombination was allowed to proceed for 24 h followed by addition of G418 antibiotic (500 μg/mL). Cells were harvested and lysed at 48 h post infection (hpi). The IVR was used to infect 100 mm2 dishes of BSC-40 cells for selection of individual antibiotic-resistant plaques for subsequent expression screening (note: a mutation in the GFP gene prevented use of fluorescent screening). This process was repeated for multiple rounds of antibiotic selection before a >98% pure virus was isolated as measured by immunoplaque assay.
iv. Expression Screening
Individual antibiotic-resistant plaques were grown in 60 mm2 dishes of BSC-40 cells to CPE and harvested in 1×SDS sample buffer [50 mM Tris-Cl pH 6.8, 2% SDS, 0.1% bromophenol blue, 10% glycerol, 100 mM β-mercaptoethanol, 1× protease inhibitor cocktail III (Research Products International Corp., Prospect, Ill.)] and then centrifuged through a QiaShredder (Qiagen) for NYVAC-KC-Gag plaques. For NYVAC-KC-dgp41, cells were lysed with RIPA lysis buffer [1% NP40, 0.1% SDS, 0.5% sodium deoxycholate, 1× protease inhibitor cocktail III, in 1×PBS without calcium or magnesium (Corning)]. RIPA lysates were mixed with an equal volume of 2×SDS sample buffer. Cell lysates were screened using SDS-PAGE as previously described (Kessans et al., 2013). Briefly, boiled samples were run on 12% polyacrylamide gels under denaturing conditions, transferred to nitrocellulose membranes (Bio-Rad) and probed with either Gag or dgp41 antibodies and anti-rabbit or anti-human IgG-HRP, respectively. Proteins were detected via chemiluminescence (ImmunoCruz Luminol Reagent, Santa Cruz).
v. Immunoplaque Assays
Immunoplaque assays were performed in 6-well dishes by infecting BSC-40s with 50 pfu from cell lysates of individual plaques. Once plaques were visible, the cells were fixed with 1:1 acetone:methanol for 30 min at −20° C., washed with PBS, then incubated with anti-p24 Gag polyclonal rabbit serum or 2F5 (obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: from Dr. Hermann Katinger) at 1:1000 in 3% FBS-PBS. Secondary biotinylated antibodies for anti-rabbit IgG or anti-human IgG from Vectastain ABC Kits (Vector Laboratories, Inc.) were used for detection with DAB peroxidase substrate (Vector Laboratories, Inc.) per manufacturer's protocol. After counting positive plaques, cells were stained with Coomassie blue dye to count the number of negative plaques. Percentages were calculated by dividing positive plaques by total plaques per well. The plaque with the highest percentage of positives was used for further purification until a plaque with >98% purity was identified and used to grow stocks.
vi. Virus Stocks
The final NYVAC-KC-Gag and NYVAC-KC-dgp41 plaques with >98% purity determined by immunoplaque assay were grown to CPE in BHK cells in a 60 mm2 dish for the first passage (P1) stock. The P1 stock was titered in BSC-40s and used to infect five T150 flasks of BHK cells at an MOI=0.01 for the P2 stock. Cells were harvested at CPE, subjected to freeze-thaw and sonication, then cell lysates were placed on a 36% sucrose pad and centrifuged at 22,000 rpm for 80 min at 4° C. with an SW28 rotor to pellet virions. Partially purified virions were resuspended in 10 mM Tris-HCl pH 9.0, their titer determined in BSC-40s, and were stored in aliquots at −80° C. until further use.
vii. Vaccinia In Vitro VLP Production
BSC-40 cells seeded in 100 mm2 dishes were infected with each of the vectors at an MOI=5 for a total MOI=10. At 24 hpi, medium and cells were harvested by centrifugation (700×g for 5 min). VLPs in the clarified medium were subjected to 40% ammonium sulfate precipitation and resuspended in 1×PBS (140 mM NaCl, 2 mM KCl, 10 mM Na2HPO4, 1 mM KH2PO4, pH 7.4). Aliquots were boiled and analyzed by SDS-PAGE for presence of Gag and dgp41 as described above.
viii. Expression in Plants of VLPs and their Purification
HIV-1 Gag/dgp41 VLPs were expressed and purified as previously described (Kessans et al., 2013). Briefly, Gag transgenic N. benthamiana plants were infiltrated with Agrobacterium tumefaciens harboring pTM 602 with the dgp41 gene and leaf tissue was harvested 4-6 days post infiltration (dpi). Leaf tissue was crushed in a blender in extraction buffer (25 mM sodium phosphate, 100 mM NaCl, 1 mM EDTA, 50 mM sodium ascorbate, 1 mM PMSF, pH 7.8). VLPs were precipitated with 40% ammonium sulfate and resuspended in 1×PBS (140 mM NaCl, 2 mM KCl, 10 mM Na2HPO4, 1 mM KH2PO4, pH 7.4), then purified via iodixanol density gradient centrifugation. The VLP-containing 20% iodixanol fraction was concentrated on a 300 kDa molecular weight cut-off membrane (Sartorius) and quantified via immunoblot for immunizations as described in (Kessans et al., 2016). A typical total yield of a highly enriched VLP preparation in terms of its HIV-1 protein constituents was 275 mg/kg and 92 mg/kg for Gag and dgp41, respectively.
ix. Antibodies
The following antibodies were used for the indicated assays: anti-p24 Gag polyclonal rabbit serum (Kessans et al., 2013); human anti-MPER 2F5 (AIDS Reagent Program and the kind gift of Morgane Bomsel); goat anti-human IgG-HRP (Sigma) for immunoblot; goat anti-rabbit IgG-HRP (Santa Cruz) for immunoblot; rabbit anti-human IgG-HRP (Santa Cruz) for ELISAs; rabbit anti-mouse IgG-HRP (Calbiochem) for ELISAs; mouse IgA-kappa (ICL Labs) for ELISAs; goat anti-mouse IgA (Sigma) for ELISAs.
x. Transmission Electron Microscopy (TEM)
BSC-40 cells grown in T75 flasks were infected with each of the vectors at an M01=5 (for a total MOI=10) and harvested by trypsinization 24 hpi. Cells were pelleted between all wash steps at 700×g for 5 min at 4° C. until embedded in agarose prior to secondary fixation. Pelleted cells were washed twice in 1×PBS (140 mM NaCl, 2 mM KCl, 10 mM Na2HPO4, 1 mM KH2PO4, pH 7.4). For primary fixation, cells were placed in 2% glutaraldehyde in PBS for 15 min at room temperature followed by a second incubation with fresh fixative for 1 h at 4° C. Fixed cells were resuspended in 1% agarose and washed three times in PBS for 30 min each at room temperature. Cells were then fixed with 1% osmium tetroxide in PBS for 1 h at room temperature followed by four 15-min washes in water. A 0.2% uranyl acetate solution in water was used to stain en bloc overnight at 4° C. followed by three 15-min washes in water. An ethanol series from 20% to 100% (anhydrous) was used for dehydration, increasing the ethanol concentration by 20% every 10 min with three incubations in anhydrous ethanol. Spurr's resin was gradually introduced through 4- to 8-h incubations with 1:3, 1:1, and 3:1 ratios of resin:100% ethanol followed by three incubations in 100% resin. Cells were divided into several blocks of Spurr's resin and polymerized at 60° C. for 36 h. Sections were cut at 70 nm thick and were placed on formvar-coated copper slot grids followed by post-stain treatment with 2% uranyl acetate and 3% Sato's lead citrate before imaging.
xi. Mouse Immunizations
All animal experiments were done with approval from the Arizona State University Institutional Animal Care and Use Committee.
Six-week-old C57BL/6 mice (Jackson Laboratories) were split into five groups. Three groups (n=5) received virus prime (VV) followed by two boosts of either mock (Group 1), VLP (Group 2), or VV+VLP (Group 3). Group 4 (n=3) received no virus prime and two VLP boosts and Group 5 served as the naive control (n=1). NYVAC-KC-Gag and NYVAC-KC-dgp41 P2 stocks, each at a dose of 5×105 pfu, were mixed together for a total dose of 1×106 pfu per mouse. Virus immunizations prepared in Tris HCl pH 9.0 were injected intramuscularly (i.m.) into the thigh. Plant-produced, gradient-purified VLPs were prepared in 1×PBS pH 7.4 with 2 μg p24 and 1.2 μg MPER and mixed with Ribi adjuvant (Sigma) per manufacturer's protocol to reach a final concentration of 2% oil [described previously in (Kessans et al., 2016)]. Mock mice were injected i.m. with Tris HCl pH 9.0 buffer in equivalent volumes. VACV and vehicle injections were delivered i.m. while VLPs were delivered intraperitoneally (i.p).
Three immunizations were given to mice at days 0, 45, and 90. Serum, fecal, and vaginal lavage samples were collected as previously described (Kessans et al., 2016) every 2 weeks at days 0, 14, 28, 42, 56, 80, and at the endpoint of day 97 for analysis of Ab production. One week post the final boost (day 97), spleens were collected for analysis of CD8 T-cell responses as described below.
Animals were monitored every 2-3 days for weight loss and other signs of illness, as a measure of vector safety.
xii. ELISA Detection of IgG and IgA
Antibody production was measured via ELISA as previously described (Kessans et al., 2016). Briefly, serum, fecal, and vaginal lavage samples were analyzed for IgG (serum) or IgA (mucosal sites) specific for Gag p24 or gp41 MPER regions. Samples were analyzed in threefold serial dilutions starting at 1:50, 1:2, and 1:5 for serum, fecal, and vaginal lavage samples, respectively. Endpoint titers were calculated as the reciprocal of the dilution factor at which OD 490 nm was equal to background levels (OD490<0.1) as previously described (Matoba et al., 2008; Kessans et al., 2016). IgG1 and IgG2a isotypes were detected with the same ELISA protocol, but with goat anti-mouse IgG1-HRP or goat anti-mouse IgG2a-HRP secondary antibodies (Santa Cruz Biotechnology) instead of total IgG. Purified mouse IgG1 kappa chain or mouse IgG2a kappa chain primary antibodies (Sigma) were used as controls.
For anti-VACV ELISAs, 96-well plates were coated with 107 pfu/well of sucrose-cushion purified NYVAC-KC in 1×PBS, and the plates were overnight at 37° C. Wells were fixed in 2% paraformaldehyde in 1×PBS for 10 min at 4° C. to inactivate the virus. Wells were washed with buffer (150 mM NaCl, 0.5% Tween-20) then blocked with 5% nonfat milk in 1×PB ST. Plates were overlaid with serially diluted serum samples and detected as previously described (Matoba et al., 2008; Kessans et al., 2016).
xiii. Intracellular Cytokine Staining and Flow Cytometry
Spleens were harvested in Hank's medium (Corning Cellgro) and cells were strained through a 70 μm filter for resuspension in complete RPMI [cRPMI: 10% FBS, penicillin (100 units/mL), streptomycin (100 μg/mL), 2 mM L-glutamine]. Red blood cells were lysed with ACK Lysing Buffer (Gibco) and splenocytes were resuspended in cRPMI at a concentration of 2×107 cells/mL. Cells were plated at 1×106 cells/well and incubated for 5 h in the presence of Golgi Plug (BD Biosciences) and 1 μg of one of five different immunodominant ZM96 Gag CD8 epitopes: LRSLYNTV (LRS8, SEQ ID NO. 7), VIPMFTAL (VIP8, SEQ ID NO. 8), AMQMLKDT (AMQ8, SEQ ID NO. 9), YSPVSILDI (YSP9, SEQ ID NO. 10), EVKNWMTDTL (EVK10, SEQ ID NO. 11) (synthesized by GenScript and resuspended according to manufacturer's protocol). Cells were stained with fluorescently conjugated antibodies: CD8-Pacific Blue, TNFα-FITC, and IFNγ-PE (BD Biosciences). Fixation and permeabilization was performed with a Cytofix/Cytoperm Kit (BD Biosciences) with final resuspension in FACS Buffer (1% FBS in 1×PBS). Samples were analyzed by flow cytometry on an LSR Fortessa. Data was analyzed using FlowJo Data Analysis Software (FlowJo, LLC; Ashland, Oreg.).
xiv. Statistics
All statistical analyses were performed in GraphPad Prism Software (GraphPad Prism Software Inc.; La Jolla, Calif.). All data were analyzed using a one-way ANOVA multiple comparison with Dunn's post-test. Significance cut-off was defined as p<0.05.
b. Generation of Recombinant Vaccinia Virus Vectors
NYVAC-KC-Gag and NYVAC-KC-dgp41 viruses were generated through in vitro recombination (see Materials and Methods) (
Gag is known to be sufficient and necessary for HIV-1 VLP formation and budding into the medium (Garoff et al., 1998). To test whether BSC-40-infected cells support VLP formation and budding, culture medium was analyzed for the presence of Gag and dgp41. Indeed, Gag protein was detected in culture medium of cells either infected with NYVAC-KC-Gag or co-infected with NYVAC-KC-Gag and NYVAC-KC-dgp41 (
c. NYVAC-KC-Gag/Dgp41 Show Cytotoxicity and In Vitro VLP Production
These results indicate that export of dgp41 to the medium depends on expression and export of Gag, suggesting that Gag VLPs and Gag/dgp41 VLPs are released, respectively, from cells that express Gag alone or co-express Gag and dgp41. Inventors used TEM to test this possibility. BSC-40 cells that were infected (MOI=5) with NYVAC-KC, NYVAC-KC-Gag, NYVAC-KC-dgp41, or co-infected with Gag/dgp4, were processed for TEM at 24 hpi.
In cells infected with the parental NYVAC-KC strain, viral replication factories are clearly visible and all stages of viral replication are easily identified (
NYVAC-KC-Gag-, dgp41-, or co-infected cells have disorganized viral factories and mature viral particles are rare (
Importantly, in cells that were infected with NYVAC-KC-Gag (
i. Mouse Immunizations
Six-week-old C57BL/6 mice were separated into five groups in order to assess different combinations of VACV and VLP immunization regimens (
Monitoring of weight revealed that none of the mice in any group lost weight (data not shown). This indicates little to no pathogenicity of the virus and is consistent with previous virulence data for NYVAC-KC (Kibler et al., 2011) and general safety of the plant-derived VLPs (Kessans et al., 2016).
d. Serum IgG Responses to Gag and MPER
Antigen-specific serum IgG responses were measured by ELISA using p24 subunit or MPER peptide to detect Gag and dgp41 Ab responses, respectively. Throughout, OD 450 nm values for the lowest dilution tested (1:50) are shown both over time (
Serum IgG responses against both p24 and MPER antigens remained undetectable in all groups until the first sample (Day 55) after the first boost. Titers increased gradually and were boosted after the final immunization with VLPs (
e. Mucosal IgA Responses to Gag and MPER
Gastrointestinal IgA responses to the dgp41 (MPER) antigen (as determined by measuring the secreted Ab levels in fecal samples) were low but detectable (
f. IgG Isotyping
The two major IgG isotypes are IgG1 and IgG2a; the former is consistent with stimulation of a Th2 response for B cell activation, whereas the latter would be indicative of a Th1 response, which primarily results in inflammatory cytokine production and killing of intracellular pathogens (Snapper and Paul, 1987; Szabo et al., 2003). Results indicated that the most important immunogens contributing to the elicitation of serum IgGs are the plant-derived VLPs. To further substantiate this conclusion, we determined the Ab isotypes contributing to this response, as protein-based vaccines (i.e. immune-complexes) usually elicit IgG1 (Mosser and Edwards, 2008; Martinez and Gordon, 2014).
To this end, serum samples from the endpoint for the two groups which showed the highest serum IgG responses (VV/VLP and VV/VV +VLP) were analyzed for their IgG isotype content by isotype-specific ELISA (
g. Anti-Vector Antibody Responses
Having substantiated the contribution of the Gag/dgp41 VLPs for the elicitation of serum Ab responses against the two HIV-1 antigens, the question arose whether or not the viral vector induced production of anti-vector (i.e. anti-VV) serum Abs. Mice belonging to Group 3 that received a total of three doses of VV (prime plus two boosts) showed significant levels of anti-VV serum IgG at the endpoint (Day 97,
h. Gag-Specific CD8 T Cell Responses
A major rationale to include Gag in an HIV-1 vaccine, especially a live-vectored one, is its excellent ability to induce cellular responses. To test induction of CD8 T cell responses, inventors tested the ability of peptides corresponding to known Gag T-cell epitopes to stimulate proliferation of CD8 T-cells among splenocytes obtained from vaccinated animals. One week after the final boost, splenocytes were harvested and stimulated with five CD8 ZM96 Gag peptides that were previously determined to be dominant in C57BL/6 mice (Chowell et al., 2015). Peptides were assessed individually in order to obtain a better resolution of their responses. CD8 T cells were analyzed for IFN-γ or TNF-α production in response to peptide stimulation using cytokine staining and flow cytometry. Little to no TNF-α production was seen in the flow cytometry analysis (data not shown); however, IFN-γ production was detectable in several groups. The group boosted with both VV and VLPs showed significant production of IFN-γ with two of the five Gag peptides, AMQ8 and EVK10, at 2.6×105 CD8+IFN-γ+ T cells (3.5% of CD8+ T cells) and 1.91×105 CD8+IFN-γ+ T cells (2.4%), respectively (
a. Experimental Procedures
i. Cloning Geminivirus-Based Vectors
The TMV-based vector, pTM 602, was previously described (Kessans et al., 2013). Geminivirus-based vectors were generously provided by Dr. Hugh Mason (Arizona State University) for cloning dgp41 and Gag. Three vectors were generated: pTM 924 (Gemini), pTM 925 which contains p19 (Gemini +p19), and pTM 901 (Dual Gem. +p19), a dual-replicon vector for simultaneous expression of two genes from the same backbone which also contains p19.
For cloning into pTM 924 and pTM 925, dgp41 was digested from pTM 602 using NcoI and SacI. The barley α-amylase (BAA) signal peptide was digested from pTM 796 using XbaI and SacI. The geminivirus backbone for pTM 924 is pTM 890 (formerly pBYR2fb) which was opened with XbaI and SacI. A triple ligation with dgp41, BAA, and the opened pTM 890 backbone using T4 DNA Ligase (Promega) yielded pTM 924. To derive pTM 925, the backbone pTM 800 was linearized using XbaI and SacI and the BAA-dgp41 insert was derived from pTM 924 by digesting with XbaI and SacI. The backbone and BAA-dgp41 fragment was ligated to yield pTM 925. Colonies were screened and sent for sequencing to confirm no mutations.
The dual-replicon vector, pTM 901, requires cloning into the XbaI/SacI cut site first due to the presence of a KpnI cut site in the multiple cloning site because the second cut site requires digestion with BsrGI and KpnI. BAA-dgp41 was excised from pTM 924 using XbaI and SacI while pTM 900 (formerly pBYR27p) was linearized using the same restriction sites. After confirming BAA-dgp41 insertion into the first cloning site, Gag was amplified from pTM 488 via PCR using AccuStart Taq DNA Polymerase HiFi (Quanta Biosciences) using oTM 776 (SEQ ID NO. 12: 5′-GAGATGTACAATGGGAGCTAGAGCCTCT-3′) and oTM 777 (SEQ ID NO. 13: 5′-GAGAGGTACCTTATTGAGAGGAAGGGT-3′) for addition of a 5′ BsrGI and 3′ KpnI cut site, shown in italics, and ligated to a TOPO TA backbone (Invitrogen). The Gag gene contained a BsrGI cut site which was removed via mutagenesis using whole plasmid replication with the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies) per manufacturer's protocol. The first reaction changed a TTG codon to CTG using primers oTM 827 (SEQ ID NO. 14: 5′-GAGGAGCTTAGGTCTCTGTACAACACAGTGGCT-3′) and oTM 828 (SEQ ID NO. 15: 5′-AGCCACTGTGTTGTACAGAGACCTAAGCTCCTC-3′) where the mutated nucleotide is underlined. However, this introduces a non-synonymous codon so an additional change from CTG to CTC was performed using oTM 829 (SEQ ID NO. 16: 5′-GAGGAGCTTAGGTCTCTCTACAACACAGTGGCT-3′) and oTM 830 (SEQ ID NO. 17: 5′-AGCCACTGTGTTGTAGAGAGACCTAAGCTCCTC-3′). Upon sequence confirmation this plasmid was named pTM 923. From there, pTM 923 and pTM 901 with BAA-dgp41 inserted were both digested using BsrGI and KpnI and then ligated together to derive the complete pTM 901. Sequences were confirmed for both Gag and dgp41 prior to use.
Each vector was transformed into GV3101 Agrobacterium tumefaciens and colony-screened to confirm transformation. An isolated colony was grown and used to start infiltration cultures for each of the three Geminivirus-based vectors.
ii. Kinetics Time Course
Six-week old Nicotiana benthamiana plants were vacuum infiltrated with an OD600=0.1 of Agrobacterium tumefaciens resuspended in infiltration buffer (10 mM MES, 10 mM magnesium sulfate heptahydrate, pH 5.5). Bacteria harboring pTM 602, 924, or 925 were infiltrated into Gag transgenic plants while pTM 901 was used in wild-type plants. Leaves were collected in triplicate every day for one week following infiltration. Collected leaves were scanned to monitor necrosis prior to flash-freezing 200 mg tissue samples in liquid nitrogen for expression analysis. Upon time-course completion, frozen tissue samples were homogenized in 1×SDS sample without dye (60 mM Tris-HCl, 100 mM DTT, 1.6% SDS (w/v), 5% glycerol) buffer using a ceramic bead in a Fast Prep-24 (MP Biomedicals, Solon, Ohio) machine twice for 30 s each. Homogenized samples were clarified by centrifugation at 14,000×g for 10 min at 4° C. Supernatant was collected and analyzed by Bradford assay (Bio-Rad) to determine total soluble protein (TSP) concentration. 20 μg TSP was loaded for each leaf sample into their respective lanes on a 12% polyacrylamide gel for SDS-PAGE followed by immunoblot as previously described (Kessans et al., 2013). Immunoblots for Gag were probed with primary polyclonal anti-p24 rabbit serum and secondary goat anti-rabbit IgG-HRP (Santa Cruz), while dgp41 blots were probed with primary human anti-gp41 2F5 (AIDS Reagents Program) and secondary goat anti-human IgG-HRP (Sigma). Coomassie staining was performed to ensure equal protein loading for each lane.
To quantify expression over time, ImageJ software (Schneider et al., 2012) was used to measure band density. For each replicate, the peak day (highest density) for Gag and dgp41 was identified and other day band densities expressed as a percentage of the peak day.
iii. Optimization of VLP Purification
Two strategies for removing rubisco from VLP preparations were tested. In the first experiment, flash-frozen leaf tissue harvested on peak expression day was homogenized in a blender in extraction buffer (25 mM sodium phosphate, 100 mM NaCl, 1 mM EDTA, 50 mM sodium ascorbate, 1 mM PMSF, pH 7.8), strained through miracloth, and insoluble protein was removed by centrifugation at 14,000×g for 20 min at 4° C. The supernatant was collected and subjected to sequential ammonium sulfate precipitation at 20% followed by 40% with VLPs pelleted at 36,000×g for 30 min at 4° C. between fractions. To remove rubisco using pH changes, after pelleting insoluble proteins, the supernatant was titrated to a pH of 5.5 to pellet rubisco followed by adjustment to pH 5.0. After each pH change protein was pelleted at 36,000×g for 30 min at 4° C. The remaining pH 5.0 supernatant was subjected to a 40% ammonium sulfate precipitation to pellet all remaining VLPs and rubisco. All pellets were resuspended in 1×PBS (140 mM NaCl, 2 mM KCl, 10 mM Na2HPO4, 1 mM KH2PO4, pH 7.4). Samples were analyzed via Bradford assay and protein loaded equally into each lane for Coomassie and SDS-PAGE as above.
iv. Large-Scale VLP Production and Purification
Six-week old N. benthamiana plants were infiltrated at OD600=0.1 with each of the four vectors. At peak expression day, as determined by the kinetics time course, leaf material was harvested in 20 g batches and flash frozen in liquid nitrogen and stored at −80° C. until extraction. VLPs were purified using 20% ammonium sulfate precipitation described above. Following precipitation VLPs were resuspended in 1×PBS and separated via iodixanol density gradient as previously described (Kessans et al., 2013). Purification progress was monitored by immunoblot by loading 5 μg total soluble protein (TSP) per lane for each step of the extraction and density gradient. Gels were used for Coomassie staining, Gag expression, or dgp41 expression as described above and in (Kessans et al., 2013).
v. VLP Quantification
VLP-containing fractions were concentrated on a 300 kDa molecular weight cut-off membrane (Sartorius) and quantified via immunoblot for total Gag and dgp41 content as previously described (Kessans et al., 2016). Ammonium sulfate pellets were directly quantified without concentrating each sample. Briefly, μg/mL amounts for both proteins were calculated by comparing serial dilutions of concentrated VLP gradient fractions and ammonium sulfate pellets to known concentrations of purified p24-CTA2 or CTB-MPER using ImageJ software to determine band density (Schneider et al., 2012). The total calculated p24 and MPER protein amount was then divided by kilograms of fresh leaf weight (FW) to determine μg/kg yield for Gag and dgp41. Molar ratio of MPER to p24 was determined by relative protein sizes (MPER=15 kDa; p24=24 kDa) for a molecular weight ratio of 1.6 p24 to MPER.
vi. Mouse Immunizations
All animal studies were conducted under the approval of the Arizona State University Institutional Animal Care and Use Committee under protocol number 15-1386R. Four to six-week old C57BL/6 mice (Jackson Laboratories; n=3) were injected i.p. with 2 μg p24 and 1.2 μg MPER gradient-purified VLPs mixed with Ribi adjuvant (Sigma) per manufacturer's protocol. Serum was collected every 2 weeks for analysis of p24 and MPER-specific IgG by ELISA as previously described (Kessans et al., 2016). Results are reported as OD 490 nm over time for the 1:50 dilution (lowest dilution tested).
b. Construction of Transient Geminivirus Vectors
The development of tobacco mosaic virus (TMV)-based vectors—known as MagnICON vectors—for transgene expression in plants has been extensively described (Marillonnet et al., 2004; Gleba et al., 2005; Marillonnet et al., 2005). A TMV vector for transiently expressing dgp41 for making HIV-1 VLPs (referred herein as TMV) was previously described (Kessans et al., 2013) (
c. Geminivirus Vectors Display Accelerated Expression
Following their introduction into Agrobacterium tumefaciens cells, agroinfiltration was used to introduce the four vectors were infiltrated into six-week old Nicotiana benthamiana plants and expression kinetics was analyzed over the course of seven days. Three of the vectors (TMV, Gemini, and Gemini+p19) were infiltrated into Gag transgenic plants to transiently express dgp41 for VLP production while the fourth vector (Dual Gemini+p19) was infiltrated into wild-type (WT) plants for transient co-expression of Gag and dgp41. Triplicate leaf samples were collected and monitored for necrosis over seven days (
Quantitative analysis of Gag and dgp41 expression reveals distinct differences between TMV and Geminivirus vectors (
Transient expression of dgp41 in the TMV vector shows initial expression at 3 dpi with a steady increase over time peaking at 7 dpi (
d. Removal of Rubisco in VLP Preparations
Two strategies were employed in an effort to reduce rubisco in VLP preparations. Rubisco bands were detected by Coomassie, staining for large bands around 50 and 25 kDa corresponding to the large and small subunits of rubisco, respectively. Gag (55 kDa) and dgp41 (23 kDa) were detected by western blot. A majority of VLPs were found to pellet with addition of 20% ammonium sulfate as determined by Gag and dgp41 presence (
e. VLP Purification and Yield
Large-scale purifications were performed for each of the four vectors harvesting at peak expression day and processing in 20 g batches. VLPs for all samples were primarily isolated to the 20% Optiprep fraction with some large aggregates accumulating in the 50% fraction (
Total expression of Gag reached a maximum around 1 mg/kg fresh leaf weight for both Dual Gemini +p19 transient expression and with the TMV vector in stable transgenics (Table 1). Transient expression of Gag and dgp41 was lowest in the Gemini vector without p19 at 0.62 mg/kg and 0.82 mg/kg, respectively (Table 1). The highest transient dgp41 expression was seen with the Dual Gemini +p19 at 5.5 mg/kg (Table 1). Both Geminivirus vectors which include p19 had higher dgp41 expression than the TMV-based vector. Interestingly, though the Gag yield in the VLP gradient fraction was similar for the TMV and Dual Gemini +p19, but the TMV vector had lower dgp41 yield (Table 2). A similar phenomenon was seen with the Gemini ±p19 vectors where inclusion of p19 during expression resulted in an increase in dgp41 yield within the VLP fraction (Table 2). Furthermore, the higher dgp41 expression in both the Gemini +p19 and Dual Gemini +p19 vectors corresponds to a higher molar ratio of MPER:p24 with an average of 2.8 and 3.3, respectively (Table 2). This indicates more dgp41 per Gag in each VLP particle, thus presenting a better immunogen with more neutralization targets.
Protein expression is expressed as mg of p24 or MPER per kg fresh leaf weight for Gag and dgp41, respectively. Triplicate samples were processed for each vector and reported here as mean with standard error.
Levels of protein are expressed as μg p24 or 1MPER for Gag and dgp41, respectively, per kg fresh leaf weight. Gag and dgp41 yield were determined in triplicate by quantitative immunoblot from density gradient VLP-enriched fractions and reported here as mean with standard error. Molar ratio of MPER to p24 is calculated as amount of dgp41 MPER to p24 Gag based on molecular weight ratio of 1.6 (p24=24 kDa/MPER=15 kDa).
f. VLPs Elicit Gag and Dgp41-Specific Antibodies in Mice
C57BL/6 mice were immunized with Gag/dgp41 VLPs produced using the TMV-based vector at Day 0 and 45. Two weeks after the first dose, p24-specific IgG is detectable in the serum while MPER-specific antibodies were below detection limit (
This application is a Continuation of U.S. patent application Ser. No. 16/396,676, filed Apr. 27, 2019 (published as US 20190328864), which claims the benefit of and priority to U.S. provisional patent application 62/663,391, filed Apr. 27, 2018, the contents of each of which are hereby incorporated by reference in their entireties.
| Number | Date | Country | |
|---|---|---|---|
| 62663391 | Apr 2018 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16396676 | Apr 2019 | US |
| Child | 17489106 | US |
